Generation of a Severe Hemophilia A Humanized Mouse Model Capable of Inducing an Anti-FVIII Immune Response., PMID:40300593
CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression., PMID:40306957
Management of Adult Acute Lymphoblastic Leukemia: A Review., PMID:40310617
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma., PMID:40312112
CD19+ B cell depletion: a novel strategy to alleviate ischemic stroke damage., PMID:40313936
Multiplex immunophenotyping of human acute myeloid leukemia patients revealed single -cell heterogeneity with special attention on therapy sensitive and therapy resistant subpopulations., PMID:40313947
Jieduquyuziyin prescription suppresses the activation of the extrafollicular effector B cell by regulating integrin αV signaling in systemic lupus erythematosus., PMID:40318773
Effect of controlled human Plasmodium falciparum infection on B cell subsets in individuals with different levels of malaria immunity., PMID:40321757
The evolving therapeutic revolution in adult acute lymphoblastic leukemia., PMID:40323723
Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD., PMID:40324063
Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease., PMID:40324120
Beyond Cellular Therapies: The Expanding Role of Antibody-Driven Immunotherapy in Pediatric Acute Lymphoblastic Leukemia., PMID:40324358
The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis., PMID:40327539
Quantification of Urine and Plasma Levels of Extracellular Vesicles in a Cohort of Kidney Transplant Recipients and Chronic Kidney Disease Patients., PMID:40332150
New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies., PMID:40332536
Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy., PMID:40336511
Targeted delivery of doxorubicin to B-cell lymphoma using monoclonal antibody-functionalized Chaetoceros biosilica., PMID:40360717
The role of blinatumomab in adult acute B lymphoblastic leukaemia., PMID:40368871
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab., PMID:40369607
Immune rejection of human mesenchymal stem cells compared to extracellular vesicles in mice with renal artery stenosis., PMID:40371959
Immune responses after one versus two Influenza A/B vaccinations in patients with multiple myeloma., PMID:40372494
Modular cell line for scalable and rapid in vitro evaluation of chimeric antigen receptors., PMID:40374131
Short-term treatment of CIDP with efgartigimod: a case series in China., PMID:40375986
Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD., PMID:40383834
Lymphocyte Subsets in Covid-19 Saudi Patients: Infection Caused Significant Reduction in Peripheral Blood Lymphocyte Subset., PMID:40387754
Optimal Structural Designs of Trispecific Antibodies to Enhance Therapeutic Efficacy in Solid Tumors and Hematological Malignancies., PMID:40402462
IGM-7354, an immunocytokine with IL-15 fused to an anti-PD-L1 IgM, induces NK and CD8+ T cell-mediated cytotoxicity of PD-L1 positive tumor cells., PMID:40402523
Revolutionizing Autoimmune Kidney Disease Treatment with Chimeric Antigen Receptor-T Cell Therapy., PMID:40405911
Extracellular Inosine Induces Anergy in B Cells to Alleviate Autoimmune Hepatitis., PMID:40409684
CD19+IL-10+ regulatory B cells induced by IL-12p35 regulates functional T-cell subsets in patients with immune thrombocytopenia., PMID:40415408
Siglec6 CAR T cells suppressed progression of AML via inhibiting Siglec6 and SHP2 induced Src and ERK signaling activation., PMID:40436895
Nanobody-Directed CEA-targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts., PMID:40439687
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study., PMID:40442445
Multi-courses of blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo-intolerant middle to high-risk pediatric B-ALL patients with invasive fungal disease., PMID:40445300
Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia., PMID:40455243
Autoantibodies Targeting Vinculin Reveal Novel Insight into the Mechanisms of Autoimmune Podocytopathies., PMID:40463498
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)., PMID:40468805
Advances in the treatment of ANCA-associated vasculitis., PMID:40473820
Monitoring anti-Rituximab antibodies in myasthenia gravis affects the time to event during Rituximab treatment., PMID:40488894
Blinatumomab Use in Pediatric B-ALL: Where are we now?, PMID:40489801
Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia., PMID:40494331
QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy., PMID:40500294
Increased Effector Memory CD4+ T Cells Are Associated with Chronic Childhood Immune Thrombocytopenia., PMID:40505868
Influence of Ovophospholipids on Lymphocyte Subsets and Humoral Immune Response in Mice., PMID:40509141
Perspectives on T-cell engaging therapies in relapsed/refractory indolent non-Hodgkin lymphoma., PMID:40511598
Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis., PMID:40512061
[Modern systemic treatment-bispecific antibodies and CAR-T cell therapy : Clinical management, mechanisms of action, outcomes]., PMID:40514410
Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863
Correlation with CD79B expression and clinicopathological parameters including cell of origin, CD79A and CD19 expression, and CD79B mutation in diffuse large B-cell lymphoma., PMID:40523447
Immune cell aberrations in Systemic Lupus Erythematosus: navigating the targeted therapies toward precision management., PMID:40524185
For research use only. Not for human or drug use.
